普米克令舒联合孟鲁司特钠治疗小儿哮喘的临床疗效评价  

Evaluation on clinical efficacy of Pulmicort Respules combined with montelukast sodium in the treatment of pediatric asthma

作　　者：景筱颖 JING Xiao-ying(Department of Pediatrics, Yingkou People's Hospital, Yingkou 115000, China)

机构地区：[1]营口人民医院儿科,115000

出　　处：《中国现代药物应用》2019年第6期5-7,共3页Chinese Journal of Modern Drug Application

摘　　要：目的研究在小儿哮喘的临床治疗中实施吸入用布地奈德混悬液(商品名:普米克令舒)联合孟鲁司特钠治疗的临床疗效。方法 30例小儿哮喘患儿,依据治疗措施的不同分为对照组及观察组,各15例。对照组给予单纯普米克令舒治疗,观察组给予普米克令舒联合孟鲁司特钠治疗。对比两组治疗效果,肺功能[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1占预计值的百分比(FEV1%预计值)]改善情况,治疗前后血清中嗜酸性粒细胞阳离子蛋白(ECP)、白细胞介素(IL)-8、IL-13变化情况。结果观察组总有效率为93.3%,高于对照组的53.3%,差异具有统计学意义(χ2=6.1364, P<0.05)。治疗前,两组患儿的FEV1%预计值、FEV1、FVC比较,差异均无统计学意义(P>0.05);治疗后,两组患儿的FEV1%预计值、FEV1、FVC均较本组治疗前升高,且观察组升高程度优于对照组,差异均具有统计学意义(P<0.05)。治疗前,两组患儿的ECP、IL-8、IL-13比较,差异均无统计学意义(P>0.05);治疗后,两组患儿的ECP、IL-8、IL-13均较本组治疗前降低,且观察组降低程度优于对照组,差异均具有统计学意义(P<0.05)。结论在小儿哮喘患儿的临床治疗中实施普米克令舒联合孟鲁司特钠的治疗效果显著,安全性、可行性较高,值得临床应用和推广。Objective To study the clinical efficacy of budesonide suspension for inhalation(trade name: Pulmicort Respules) combined with montelukast sodium in clinical treatment of pediatric asthma. Methods A total of 30 children with asthma were divided by different treatment measures into control group and observation group, with 15 cases in each group. The control group was treated with Pulmicort Respules, and the observation group was treated with Pulmicort Respules combined with montelukast sodium. Comparison were made on treatment effect, lung function [forced expiratory volume in the first second(FEV1), forced vital capacity(FVC), and the percentage of FEV1 to the predicted value(FEV1% predicted value)] improvement, changes of serum eosinophil cationic protein(ECP), interleukin(IL)-8 and IL-13 before and after treatment between the two groups. Results The observation group had higher total effective rate as 93.3% than 53.3% in the control group, and the difference was statistically significant(χ^2=6.1364, P<0.05). Before treatment, both groups had no statistically significant in FEV1% predicted value, FEV1 and FVC(P>0.05). After treatment, both groups had higher FEV1% predicted value, FEV1 and FVC than those before treatment, and the observation group was higher than the control group. Their difference was statistically significant(P<0.05). Before treatment, both groups had no statistically significant in ECP, IL-8 and IL-13(P>0.05). After treatment, both groups had lower ECP, IL-8 and IL-13 than those before treatment, and the observation group was lower than the control group. Their difference was statistically significant(P<0.05). Conclusion Combination of Pulmicort Respules and montelukast sodium shows remarkable effect in clinical treatment of pediatric asthma with higher safety and feasibility. It is worhty of clinical application and promotion.

关 键 词：吸入用布地奈德混悬液 孟鲁司特钠 小儿哮喘 临床疗效 

分 类 号：R725.6[医药卫生—儿科]